A non-absorbable rifamycin for treatment of hepatic encephalopathy

R. Testa, C. Eftimiadi, G. S. Sukkar, C. De Leo, S. Rovida, G. C. Schito, G. Celle

Research output: Contribution to journalArticlepeer-review

Abstract

Ammonia (NH3) plays a role in hepatic encephalopathy (HE). Agents fecting colonic ammonia production, such as non-absorbable antibiotics, ?rdecrease plasma levels of NH3 and findings of HE. The short-term efficacy of a non-absorbable rifamycin, rifaximin, was studied in comparison with paramomycin in 20 cirrhotic patients with high levels of NH3 and impaired number connection test (NCT). Both antibiotics significantly decreased ammonia-producing colonic bacteria. Rifaximin proved to be active on both aerobic and anaerobic bacteria and is thus effective, even at the dosage used, in the treatment of HE.

Original languageEnglish
Pages (from-to)387-392
Number of pages6
JournalDrugs under Experimental and Clinical Research
Volume11
Issue number6
Publication statusPublished - 1985

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology (medical)
  • Pharmacology
  • Drug Discovery

Fingerprint Dive into the research topics of 'A non-absorbable rifamycin for treatment of hepatic encephalopathy'. Together they form a unique fingerprint.

Cite this